



31 July 2025

Company Announcements Office
Australian Securities Exchange

QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

In accordance with ASX Listing Rule 4.7B, Vectus Biosystems Limited (Vectus or the Company) presents its June 2025 Quarterly Activities Report and Quarterly Cash Flow Report – Appendix 4C.

Commentary on Activities for June 2025 Quarter

The Company continues to prosecute its key patents supporting its library of small molecules targeting cardiac fibrosis, and renal (kidney), hepatic (liver) and lung fibrosis. The granted Vectus patents cover both the specifics of the orally-doseable small molecules and a proprietary method of manufacture.

The Company is working closely on its commercialisation programme with Martina Molsbergen of the international firm, C14 Consulting Group, LLC (C14), based in the USA. C14 has confirmed that a number of active licensing / strategic discussions are being undertaken on behalf of Vectus in relation to its lead compound, VB0004, together with the Company's other drug candidates A32, A79 and P5 from Vectus' extensive drug library.

The Company has transferred additional data received in relation to the VB0004 safety trials to C14, and Vectus has updated its data room containing a broad portfolio of intellectual property (IP), data and information in relation to the Company's key assets. C14 continues to receive requests for access to Vectus' data room and there are active discussions taking place.

The Company and C14 are investigating potential licencees for the Chinese domestic market. Vectus has successfully validated production of VB0004 in China and the Company is examining the opportunity for a faster approval in China on the basis of its now-validated safety profile of VB0004. Vectus has been advised that there is precedent for this accelerated approval path and is seeking collaboration with Chinese companies that may be able to assist in bringing VB0004 forward in the domestic Chinese market.

Phase Ia/Ib Human Clinical Trials

The Company has now received the additional information from the previous Phase Ia and Ib human clinical trials. After analysing this data, Vectus confirms that the safety profile previously determined for VB0004 has been further validated by the recent clinical data. This information is now being made available to interested parties that execute confidentiality agreements and is available in the Company's data room.

Finance and Corporate

Vectus has significantly reduced its operating costs, and is now largely focussed on potential licensing opportunities and a variety of collaborations. The funds expended by the Company during the June 2025 quarter were in connection with the finalisation of the Phase I clinical trials and commercialisation of VB0004, together with IP renewals and corporate overheads. These payments for commercialisation, Phase I, research, patents and staff costs for the quarter amounted to \$273,000. Cash-on-hand at 30 June 2025 was \$251,000, and Vectus is utilising a line of credit provided by one of the Directors. The Company is working on the submission of a research and development cash-back claim to obtain an estimated \$420,000 from the Australian Taxation Office, which is anticipated to be received in late September 2025. There were no payments to related parties during the quarter. Vectus continues to evaluate a number of options to address its future capital requirements and is examining the opportunity for potential partners or licencees to fund further clinical studies.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

Ground Floor, Unit 5, 26-34 Dunning Avenue, Rosebery NSW 2018 Australia

Telephone: +61 2 8344 1300; Facsimile: +61 2 9697 0944

Email: info@vectusbiosystems.com.au

Website: www.vectusbiosystems.com.au

This report was authorised by the Company's Board of Directors.

Vectus Biosystems Limited

Ron Shnier

Chairman

About Vectus Biosystems Limited

The Company is developing treatments for fibrosis, including for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Vectus successfully completed its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX:VBS) and commenced trading on ASX on 23 February 2016, after raising \$5.1 million. Funds from the IPO and from two subsequent fundraisings were used predominantly to develop the Company's lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 has progressed through a number of important milestones, including pharmaceutical scale-up and additional toxicity studies, its Human Phase Ia and Ib human trials of VB0004, and the advancement of other drugs in its library. This fits with the Company's strategy of developing, and the performance of early validation work on, its drug candidates to the point where they become commercially attractive to pharmaceutical partners.

Vectus has also developed technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The technology, called Accugen, is owned by the Company's wholly-owned subsidiary Accugen Pty Limited. The technology offers a time, cost and accuracy benefit compared to currently-available systems. Vectus' current stage of investment in Accugen is a commercialisation programme that may include direct sales, distribution partnerships and licensing opportunities.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Vectus Biosystems Limited

ABN

54 117 526 137

Quarter ended ("current quarter")

30 June 2025

Consolidated statement of cash flows

1 Cash flows from operating activities

1.1 Receipts from customers

1.2 Payments for

(a) patent and research expenses

(b) staff costs and directors' fees

(c) occupancy cost

(d) corporate overheads

(e) legal and professional fees

(f) other operating items

1.3 Dividends received

1.4 Interest and other items of a similar nature received

1.5 Interest and other costs of finance paid

1.6 Income tax refund received (including R&D tax offset)

1.7 Government grants and tax incentives

1.8 Others (provide details if material)

1.9 Net cash from / (used in) operating activities

Current quarter \$A'000	Year to date (12 months) \$A'000
-	-
(223)	(793)
(50)	(548)
-	(24)
(29)	(313)
(24)	(174)
5	28
-	-
2	18
-	-
-	977
-	-
-	-
(319)	(829)

Consolidated statement of cash flows

	Current quarter \$A'000	Year to date (12 months) \$A'000
2 Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	(30)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	101
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	-	71
3 Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5 Proceeds from borrowings	200	200
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	200	200

Consolidated statement of cash flows

	Current quarter \$A'000	Year to date (12 months) \$A'000
4 Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	370	809
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(319)	(829)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	71
4.4 Net cash from / (used in) financing activities (item 3.10 above)	200	200
4.5 Effect of movement in exchange rates on cash held	-	-
4.6 Cash and cash equivalents at end of period	251	251

5 Reconciliation of cash and cash equivalents

Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts

	Current quarter \$A'000	Previous quarter \$A'000
5.1 Cash on hand and at bank	251	370
5.2 Term Deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (item 4.6)	251	370

6 Payments to related parties of the entity and their associates

	Current quarter \$A'000
6.1 Aggregate amount of payments to related parties and their associates included in item 1	-
6.2 Aggregate amount of payments to related parties and their associates included in item 2	-

7 Financing facilities

Note: The term "facility" includes all forms of financing arrangements available to the entity

Add notes as necessary for an understanding of the sources of finance available to the entity

	Total facility \$A'000	Amount drawn \$A'000
7.1 Loan facilities	200	200
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	200	200
7.5 Unused financing facilities available at quarter end		-

- 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

The loan facility of \$200,000 has been entered into with Director Maurie Stang and additional loan facilities are currently being negotiated. Any drawdown of the facilities can be repaid without penalty if Vectus secures alternative funding. Drawdowns of the loan are to be repaid from future receipts from the Australian Taxation Office (ATO) of research and development (R&D) cash-back or from other funds received. The first drawdown of the facility was made in June 2025.

8 Estimated cash available for future operating activities

	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(319)
8.2 Cash and cash equivalents at quarter end (item 4.6)	251
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	251
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	0.79

- 8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

- 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

As previously announced, the level of expenditure has been very significantly reduced as the Phase Ib human clinical trials have been finalised and the Company is now focussing its research and IP activities to support its commercialisation activities. The Company has re-located to new premises that provide far lower costs and Vectus has come to arrangements that will defer certain significant operating costs through 2025. Following a review with the Company's taxation consultants, an amount of \$420,000 is expected to be received from the ATO in late September 2025 as a refund for 2024-25 expenditure incurred on R&D.

- 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

The Company continues to evaluate a number of options to address its future capital requirements, and is actively pursuing licensing opportunities, which, if successful, may provide upfront payments to Vectus and annuity revenue going forward.

- 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

The Company expects to be able to continue its operations, and to meet its business objectives, based on its reduced overheads and the matters outlined in 8.6.1 and 8.6.2.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **31 July 2025**

Authorised for release to the market by the Vectus Board of Directors.

Notes:

- 1 This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- 2 If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4 If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- 5 If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.